Data Sheet

Product Name:	L-JNKI-1
Cat. No.:	CS-0031499
Molecular Formula:	C164H286N66O40
Molecular Weight:	3822.44
Target:	JNK
Pathway:	MAPK/ERK Pathway
Solubility:	H2O : ≥ 100 mg/mL (26.16 mM)

DQSRPVQPFLNLTTPRKPRPPRRRQRRKKRG-NH2

BIOLOGICAL ACTIVITY:

L-JNKI-1 is a cell-permeable peptide inhibitor specific for **JNK**. IC50 & Target: JNK[1]. **In Vivo:** L-JNKI-1 has been shown to effectively inhibit JNK activity in in vivo studies. It is shown that Ang II induces a dose-dependent pressor response, which was significantly attenuated by JNK inhibition[1]. It is also found that 10 μM L-JNKI-1 decreases phosphorylated c-Jun by 98% and phosphorylated Elk-1 by 100%. L-JNKI-1 is able to across the blood-brain barrier and penetrate neurons of adult mice and P5 rats within 1 h after an intraperitoneal injection[2].

PROTOCOL (Extracted from published papers and Only for reference)

Animal Administration: [1]Rats[1]

Six-week-old male SD **rats** are used. The rats are injected with a bolus of JNK peptide inhibitor **L-JNKI-1 (5 mg/kg)** followed by infusion of JNKI 1 (5 mg/kg per hour) until the completion of the experiment. After a 30-minute infusion of JNK inhibitor, the pressor response to Ang II at the 3 doses described above is determined at 30-minute intervals[1].

References:

[1]. Zhou MS, et al. Role of c-Jun N-terminal kinase in the regulation of vascular tone. J Cardiovasc Pharmacol Ther. 2010 Mar;15(1):78-83.

[2]. Borsello T, et al. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat Med. 2003 Sep;9(9):1180-6.

CAIndexNames:

GRKKRRQRRRPPRPKRPTTLNLFPQVPRSQD

SMILES:

[DQSRPVQPFLNLTTPRKPRPPRRRQRRKKRG-NH2]

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA